OrbiMed13F
Carl Gordon · Biotech · quarter ending 2026-06-30, filed 2026-08-14 · SEC filing
Stock portfolio
$5.3B
Positions
117
Above their Pivot
49%
New positions
15
New positions this quarter
Sold out completely
Holdings
| Stock | Weight | Value | Last quarter | vs Pivot | Score | Trend | Other whales |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | 12.0% | $630.5M | no change | +9.4% | 45 | Above its Pivot | 3 |
| ELVN Enliven Therapeutics | 6.5% | $343.9M | trimmed 15% | -1.8% | 36 | Below its Pivot | 1 |
| LLY ELI Lilly & | 5.9% | $309.3M | added 9% | +17.4% | 70 | Above its Pivot | 9 |
| MBX MBX Biosciences | 3.6% | $189.3M | trimmed 6% | +7.5% | 28 | Above its Pivot | 0 |
| AZN Astrazeneca | 3.2% | $171.1M | added 37% | -5.0% | 73 | Below its Pivot | 2 |
| GPCR Structure Therapeutics | 2.2% | $118.6M | added 50% | -57.9% | 20 | Below its Pivot | 1 |
| SION Sionna Therapeutics | 2.1% | $112.4M | trimmed 28% | -88.4% | 20 | Below its Pivot | 4 |
| CRVS Corvus Pharmaceuticals | 2.0% | $107.0M | no change | -26.6% | 48 | Below its Pivot | 2 |
| AVBP Arrivent Biopharma | 2.0% | $105.2M | no change | -22.5% | 32 | Below its Pivot | 0 |
| GH Guardant Health | 1.7% | $87.6M | added 34% | +31.4% | 35 | Above its Pivot | 1 |
| ARGX Argenx SE | 1.6% | $86.2M | trimmed 32% | +2.5% | 44 | Above its Pivot | 0 |
| MRK Merck & | 1.6% | $85.2M | no change | +15.4% | 59 | Above its Pivot | 5 |
| QURE Uniqure | 1.6% | $83.3M | trimmed 15% | -24.3% | 47 | Below its Pivot | 1 |
| PRAX Praxis Precision Medicines | 1.5% | $77.0M | added 33% | -19.7% | 35 | Below its Pivot | 2 |
| EW Edwards Lifesciences | 1.4% | $75.5M | trimmed 32% | +4.5% | 56 | Above its Pivot | 2 |
| PRLD Prelude Therapeutics | 1.4% | $73.2M | added 26% | -8.6% | 45 | Below its Pivot | 2 |
| ABVX Abivax | 1.4% | $72.8M | added 17% | -23.4% | 44 | Below its Pivot | 2 |
| DYN Dyne Therapeutics | 1.4% | $71.9M | added 11% | -19.2% | 51 | Below its Pivot | 2 |
| NTRA Natera | 1.4% | $71.1M | no change | +54.4% | 40 | Above its Pivot | 4 |
| CGON CG Oncology | 1.3% | $69.1M | added 3% | -5.9% | 27 | Below its Pivot | 0 |
| UNH Unitedhealth | 1.3% | $67.0M | New buy | +15.8% | 73 | Above its Pivot | 11 |
| SPRY ARS Pharmaceuticals | 1.3% | $66.4M | no change | -46.9% | 43 | Below its Pivot | 2 |
| ASND Ascendis Pharma A/S | 1.2% | $65.2M | +2.6% | 67 | Above its Pivot | 2 | |
| HUM Humana | 1.2% | $65.2M | New buy | +38.5% | 57 | Above its Pivot | 1 |
| COGT Cogent Biosciences | 1.2% | $65.1M | added 422% | -12.8% | 52 | Below its Pivot | 0 |
| BSX Boston Scientific | 1.2% | $63.3M | trimmed 38% | -21.0% | 68 | Below its Pivot | 4 |
| ISRG Intuitive Surgical | 1.2% | $62.8M | trimmed 24% | +3.7% | 77 | Above its Pivot | 5 |
| MLYS Mineralys Therapeutics | 1.1% | $56.9M | added 3% | -24.8% | 37 | Below its Pivot | 1 |
| ODTX Odyssey Therapeutics | 1.1% | $56.2M | New buy | — | — | 0 | |
| XENE Xenon Pharmaceuticals | 1.0% | $53.9M | trimmed 16% | -32.7% | 39 | Below its Pivot | 2 |
| ARQT Arcutis Biotherapeutics | 1.0% | $53.5M | New buy | +24.1% | 72 | Above its Pivot | 0 |
| BMY Bristol-myers Squibb | 1.0% | $53.3M | no change | +2.8% | 58 | Above its Pivot | 1 |
| QTTB Q32 BIO | 1.0% | $52.6M | added 83% | -5.0% | 54 | Below its Pivot | 1 |
| SYK Stryker | 0.9% | $50.1M | trimmed 13% | -5.6% | 69 | Below its Pivot | 1 |
| CAI Caris Life Sciences | 0.9% | $50.0M | no change | +49.6% | 57 | Above its Pivot | 2 |
| TMO Thermo Fisher Scientific | 0.9% | $45.5M | added 95% | +22.7% | 49 | Above its Pivot | 6 |
| PVLA Palvella Therapeutics | 0.8% | $44.7M | added 117% | -0.6% | 43 | Below its Pivot | 0 |
| ELV Elevance Health | 0.8% | $44.4M | no change | +18.5% | 80 | Above its Pivot | 1 |
| STTK Shattuck Labs | 0.8% | $43.8M | no change | -8.6% | 35 | Below its Pivot | 0 |
| UPB Upstream BIO | 0.8% | $39.4M | no change | -72.5% | 14 | Below its Pivot | 0 |
| CRNX Crinetics Pharmaceuticals | 0.7% | $37.4M | no change | — | — | 1 | |
| RYTM Rhythm Pharmaceuticals | 0.7% | $35.9M | added 3% | -8.4% | 43 | Below its Pivot | 4 |
| SNDX Syndax Pharmaceuticals | 0.6% | $33.7M | added 60% | -34.4% | 15 | Below its Pivot | 0 |
| FBRX Forte Biosciences | 0.6% | $33.5M | added 32% | — | — | 0 | |
| CMPX Compass Therapeutics | 0.6% | $33.3M | no change | — | — | 0 | |
| NKTR Nektar Therapeutics | 0.6% | $32.5M | added 69% | -42.8% | 35 | Below its Pivot | 0 |
| KRYS Krystal Biotech | 0.6% | $30.9M | added 20% | +1.4% | 34 | Above its Pivot | 0 |
| AXSM Axsome Therapeutics | 0.6% | $28.8M | trimmed 45% | -27.5% | 19 | Below its Pivot | 1 |
| KNSA Kiniksa Pharmaceuticals In | 0.5% | $26.9M | added 133% | +30.1% | 51 | Above its Pivot | 1 |
| TRVI Trevi Therapeutics | 0.5% | $26.7M | trimmed 42% | -11.8% | 37 | Below its Pivot | 1 |
| IRON Disc Medicine | 0.5% | $26.2M | trimmed 67% | +5.5% | 64 | Above its Pivot | 2 |
| WST West Pharmaceutical Svsc | 0.5% | $25.3M | New buy | +26.5% | 67 | Above its Pivot | 1 |
| RLMD Relmada Therapeutics | 0.5% | $25.1M | trimmed 23% | -39.2% | 43 | Below its Pivot | 0 |
| URGN Urogen Pharma | 0.5% | $24.9M | trimmed 23% | +11.3% | 20 | Above its Pivot | 0 |
| STRO Sutro Biopharma | 0.5% | $24.7M | trimmed 7% | -59.6% | 23 | Below its Pivot | 1 |
| SVRA Savara | 0.5% | $24.4M | added 524% | -22.1% | 35 | Below its Pivot | 0 |
| NPCE Neuropace | 0.5% | $23.9M | trimmed 28% | -14.4% | 47 | Below its Pivot | 0 |
| AURA Aura Biosciences | 0.5% | $23.7M | New buy | -5.8% | 52 | Below its Pivot | 1 |
| ORIC Oric Pharmaceuticals | 0.4% | $21.8M | trimmed 25% | +18.1% | 56 | Above its Pivot | 1 |
| HELP Cybin | 0.4% | $21.6M | trimmed 15% | +33.4% | 40 | Above its Pivot | 0 |
| BCRX Biocryst Pharmaceuticals | 0.3% | $18.5M | added 30% | -12.2% | 41 | Below its Pivot | 2 |
| BIOA Bioage Labs | 0.3% | $18.4M | added 6% | -68.4% | 29 | Below its Pivot | 1 |
| LXEO Lexeo Therapeutics | 0.3% | $18.4M | added 10% | -47.7% | 32 | Below its Pivot | 1 |
| WHWK Whitehawk Therapeutics | 0.3% | $18.0M | trimmed 6% | -16.1% | 35 | Below its Pivot | 0 |
| DFTX Definium Therapeutics | 0.3% | $17.2M | trimmed 55% | +22.8% | 48 | Above its Pivot | 2 |
| SYRE Spyre Therapeutics | 0.3% | $16.5M | New buy | +26.2% | 47 | Above its Pivot | 1 |
| CRBP Corbus Pharmaceuticals | 0.3% | $16.3M | no change | -53.6% | 13 | Below its Pivot | 0 |
| VERA Vera Therapeutics | 0.3% | $15.9M | no change | -25.2% | 43 | Below its Pivot | 0 |
| ALMS Alumis | 0.3% | $15.4M | no change | -68.9% | 49 | Below its Pivot | 1 |
| EYPT Eyepoint | 0.3% | $15.3M | no change | — | — | 0 | |
| WAT Waters | 0.3% | $15.1M | New buy | +23.4% | 59 | Above its Pivot | 2 |
| MNPR Monopar Therapeutics | 0.3% | $14.6M | New buy | -8.3% | 38 | Below its Pivot | 1 |
| TVTX Travere Therapeutics | 0.3% | $14.4M | New buy | +8.5% | 27 | Above its Pivot | 1 |
| TSHA Taysha Gene Therapies | 0.3% | $13.6M | New buy | -25.9% | 38 | Below its Pivot | 2 |
| BIIB Biogen | 0.2% | $13.3M | no change | +25.7% | 75 | Above its Pivot | 1 |
| RVMD Revolution Medicines | 0.2% | $13.2M | added 36% | +21.2% | 37 | Above its Pivot | 3 |
| DNTH Dianthus Therapeutics | 0.2% | $11.2M | New buy | -8.6% | 28 | Below its Pivot | 1 |
| SPRB Spruce Biosciences | 0.2% | $10.8M | New buy | -20.2% | 49 | Below its Pivot | 0 |
Largest 78 of 117 positions. Click any stock for its trend and everyone else who owns it.
Follow the whales after every closeThe free daily email flags when a stock the big funds own breaks its Pivot or docks.
Get it free → All the whales
Get it free → All the whales
Source: Form 13F-HR on SEC EDGAR. 13Fs are filed up to 45 days after the quarter ends and show only long US-listed positions.